• Profile
Close

Bremelanotide for the treatment of hypoactive sexual desire disorder: Two randomized phase 3 trials

Obstetrics and Gynecology Nov 04, 2019

Kingsberg S, Clayton A, Clayton D, et al. - Researchers investigated whether bremelanotide is a safe and efficacious treatment option for premenopausal women with hypoactive sexual desire disorder. In two identical phase 3, randomized, double-blind, placebo-controlled, multicenter clinical trials (RECONNECT), bremelanotide 1.75 mg was administered subcutaneously as needed in premenopausal women with hypoactive sexual desire disorder. Randomization of patients 1:1 to 24 weeks of treatment with bremelanotide or placebo was done. Findings from both studies illustrate the efficacy of bremelanotide in improving sexual desire and related distress in premenopausal women with hypoactive sexual desire disorder. The drug had a favorable safety profile with most treatment-emergent adverse events related to tolerability; the majority of these were mild or moderate in intensity.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay